Akero Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Tomas J. Heyman, a director at Akero Therapeutics, Inc., disposed of all his common stock and stock options following the company's merger with Novo Nordisk A/S.
Akero Therapeutics director Yuan Xu disposed of all beneficial ownership in the company following its acquisition by Novo Nordisk.
Akero Therapeutics President and CEO, Andrew Cheng, converted all his common stock, RSUs, and stock options into cash and contingent value rights following the company's merger with Novo Nordisk's subsidiary.
Akero Therapeutics director Seth Loring Harrison disposed of all common stock and options following the company's acquisition by Novo Nordisk, receiving cash and contingent value rights.
Akero Therapeutics Director Graham G. Walmsley disposed of common stock, restricted stock units, and stock options following the company's merger with Novo Nordisk A/S, receiving cash and contingent value rights.
Akero Therapeutics Director Judy Chou converted her restricted stock units and stock options into cash and contingent value rights following the merger with Novo Nordisk.
Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, disposed of common stock, restricted stock units, and stock options following the company's merger with Novo Nordisk A/S, receiving cash and contingent value rights.
Akero Therapeutics Director Mark T. Iwicki disposed of common stock and stock options following the acquisition by Novo Nordisk A/S, receiving cash and contingent value rights.
Akero Therapeutics Chief Technology Officer Scott A. Gangloff's equity holdings were converted into cash and contingent value rights following the merger with Novo Nordisk.
Akero Therapeutics' CFO, William Richard White, disposed of common stock, RSUs, and stock options following the company's acquisition by Novo Nordisk.
Akero Therapeutics' Chief Development Officer, Catriona Yale, disposed of common stock, RSUs, and stock options following the company's merger with Novo Nordisk, receiving cash and contingent value rights.
Akero Therapeutics Senior VP Patrick Lamy disposed of common stock, restricted stock units, and stock options following the company's acquisition by Novo Nordisk, receiving cash and contingent value rights.
Akero Therapeutics director Jane Henderson disposed of all her beneficial ownership in the company following its merger with Novo Nordisk, receiving cash and contingent value rights for her equity.
Akero Therapeutics' Chief Operating Officer, Jonathan Young, disposed of all his direct and indirect holdings, including common stock, RSUs, and stock options, following the company's acquisition by Novo Nordisk A/S for $54.00 cash plus a $6.00 CVR.
Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, exercised a significant number of stock options, acquiring 152,678 shares of common stock.
Akero Therapeutics' Chief Operating Officer, Jonathan Young, reported exercising stock options and gifting a portion of his common stock holdings.
Akero Therapeutics President and CEO, Andrew Cheng, donated 74,538 shares of common stock to a donor advised fund.
Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, gifted 37,100 shares of common stock to a donor-advised fund.
Akero Therapeutics President and CEO, Andrew Cheng, reported gifting 14,739 shares of common stock to a 501(c)(3) charitable organization.
Akero Therapeutics' Chief Development Officer, Catriona Yale, exercised stock options to acquire 8,266 shares of common stock.
Akero Therapeutics President and CEO, Andrew Cheng, exercised stock options and subsequently sold 30,000 shares of common stock under a pre-arranged 10b5-1 trading plan.
Akero Therapeutics Director Graham G. Walmsley exercised multiple stock options, acquiring 93,000 shares of common stock on October 8, 2025.
Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, sold a total of 12,500 shares of common stock on October 7, 2025, following the exercise of stock options.
Akero Therapeutics President and CEO, Andrew Cheng, exercised 52,212 stock options at $0.615 per share, increasing his direct common stock holdings.
Akero Therapeutics' COO, Jonathan Young, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged trading plan.
Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 586 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
Akero Therapeutics' Chief Development Officer, Catriona Yale, sold 659 shares of common stock at $43.02 per share to cover tax withholding obligations related to restricted stock unit vesting.
Akero Therapeutics' Chief Financial Officer, William Richard White, sold 659 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, sold 553 shares of common stock at $43.02 per share to cover tax withholding obligations related to restricted stock unit vesting.
Akero Therapeutics' President and CEO, Andrew Cheng, exercised stock options and subsequently sold a portion of his common stock holdings, including shares for tax obligations, under a pre-arranged 10b5-1 plan.